BioMed Research International / 2013 / Article / Tab 3 / Clinical Study
TET2 Mutations in Ph-Negative Myeloproliferative Neoplasms: Identification of Three Novel Mutations and Relationship with Clinical and Laboratory Findings Table 3 Clinical and laboratory features of 97 MPNs patients stratified by TET2 status.
TET2-positive MPN (
) TET2-negative MPN (
)
valueDiagnosis MPN-U (
) 3 (37.5%) 5/8 (62.5%) ET (
) 2 (3.6%) 53 (96.4%) 0.005 PV (
) 2 (8.0%) 23 (92%) IMF (
) 0 9 Median age, years (range) 71 (43–76) 65.5 (25–89) 0.57 Follow-up months, median (range) 38.6 (13.3–130) 54.2 (4.3–195.7) 0.38 Hb, g/100 mL (range) 16.1 (13.3–19.9) 15.2 (11.1–21.5) 0.22 WBC × 109 /L (range) 6.86 (5.4–12.4) 8.56 (1.7–19.6) 0.3 Monocytes × 109 /L (range) 0.3 (0.1–1.15) 0.45 (0.02–0.9) 0.45 Plt × 109 /L (range) 476 (134–849) 629 (149–1750) 0.02 JAK 2 V617F
(%) 6/7 (85.7) 66/90 (73.3) 0.78 JAK 2 V617F burden median % (range) 24 (5–65) 25 (5–90) 0.99 EEC
(%) 4/7 (57.1) 71/90 (78.8) 0.39 CFU-MK
(%) 1/7 (14.2) 57/90 (63.3) 0.01 CD34 + SP × 109 /L (range) 0.021 (0.0103–0.273) 0.03 (0.0015–0.61) 0.89 CD34 + SP (%) (range) 0.03 (0.02–0.35) 0.035 (0.0015–0.56) 0.43 Bone marrow cellularity % (range) 50 (30–80) 50 (20–98) 0.96 Single cytogenetic abnormality (
) 0/7 5/90 (5.5) 0.49 Complex karyotype (
) 0/7 1/90 (1.1) Trisomy (
) 0/7 1/90 (1.1) Pruritus (
) 2/7 21/90 0.88 Palpable splenomegaly (
) 2/7 37/90 0.8 Splenic square cm2 (range) 40 (31–105) 42 (25–200) 0.45 Arterial thromboses (
) 1/7 21/90 0.43 Venous thromboses (
) 2/7 7/90 Spontaneous haemorrhage (
) 0/7 2/90 0.58 Posttraumatic haemorrhage (
) 0/7 2/90 Cytoreductive treatment (
) 7/7 86/90 0.66